Positive Results from Phase III PROfound Trial of Olaparib Demonstrate Improvements in OS

Results from the trial showed a statistically significant and clinically meaningful improvement in overall survival with olaparib versus enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer selected for BRCA1/2 or ATM gene mutations.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news